Innoviva Q4 revenue up 25%, net income soars

Innoviva

25/02/2026 21:27

Overview

Biopharmaceutical firm's Q4 revenue rose 25% yr/yr, driven by net product sales growth

Q4 net income surged by 707%, aided by higher revenue and investment value gains

Company initiated $125 mln share repurchase program in Q4

Outlook

Innoviva anticipates IST U.S. net product sales to exceed $150 mln in 2026

Company plans to commercialize NUZOLVENCE in H2 2026

Result Drivers

IST SALES GROWTH - IST achieved 47% year-over-year growth in U.S. net product sales

INVESTMENT GAINS - Net income was boosted by favorable changes in the fair values of equity and long-term investments, particularly in Armata Pharmaceuticals

Company press release: ID:nBw8f2w4wa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Royalty Revenue
$54.90 mln
Q4 Net Income
$164.15 mln
Q4 Pretax Profit
$195.04 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Innoviva Inc is $35.00, about 49.4% above its February 24 closing price of $23.42

The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 9 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)